{"id":33487,"date":"2025-05-20T14:00:00","date_gmt":"2025-05-20T12:00:00","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=33487"},"modified":"2025-09-10T08:37:22","modified_gmt":"2025-09-10T06:37:22","slug":"risultati-preliminari-delleroe","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/it\/risultati-preliminari-delleroe\/","title":{"rendered":"Risultati preliminari promettenti dallo studio HERO per la sindrome"},"content":{"rendered":"<p>All'inizio di quest'anno, Alvin Luk ha preso parte all'evento <em>Medicina CRISPR<\/em> a Copenaghen per fornire un aggiornamento sullo studio clinico HERO per la sindrome da duplicazione del gene MECP2. La sua presentazione \u00e8 disponibile per la comunit\u00e0 su YouTube.<\/p>\n\n\n\n<p>In questo video scoprirete la terapia sperimentale CRISPR-Cas13 di Huidagene, <strong>HG204<\/strong>e i progressi del primo bambino trattato, tre mesi dopo aver ricevuto il farmaco sperimentale. Ci vediamo al <strong>minuto 26:00<\/strong> per visualizzare le immagini del paziente.<\/p>\n\n\n\n<p>Questi primi risultati sono molto incoraggianti e suggeriscono ancora una volta che il ripristino dei livelli di proteina MeCP2 potrebbe essere una strategia promettente per combattere la sindrome.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"560\" src=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1024x560.png\" alt=\"\" class=\"wp-image-33492\" srcset=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1024x560.png 1024w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-300x164.png 300w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-768x420.png 768w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1536x841.png 1536w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-18x10.png 18w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025.png 1842w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"576\" data-id=\"33489\" data-src=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-4-1024x576.png\" alt=\"\" class=\"wp-image-33489 lazyload\" data-srcset=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-4-1024x576.png 1024w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-4-300x169.png 300w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-4-768x432.png 768w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-4-1536x864.png 1536w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-4-18x10.png 18w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-4.png 2008w\" data-sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/576;\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"575\" data-id=\"33490\" data-src=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1-1024x575.png\" alt=\"\" class=\"wp-image-33490 lazyload\" data-srcset=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1-1024x575.png 1024w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1-300x168.png 300w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1-768x431.png 768w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-1.png 2006w\" data-sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/575;\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"576\" data-id=\"33491\" data-src=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-3-1024x576.png\" alt=\"\" class=\"wp-image-33491 lazyload\" data-srcset=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-3-1024x576.png 1024w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-3-300x169.png 300w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-3-768x432.png 768w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-3-1536x864.png 1536w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-3-18x10.png 18w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-CRISPR-conference-2025-3.png 2007w\" data-sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1024px; --smush-placeholder-aspect-ratio: 1024\/576;\" \/><\/figure>\n<\/figure>\n\n\n\n<p>Un secondo bambino \u00e8 gi\u00e0 stato trattato con HG204 e si prevede che fino a sei pazienti saranno inclusi successivamente in questo studio in Cina.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-white-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/www.youtube.com\/watch?v=uVFNm1UWQv8\" style=\"border-radius:11px;background-color:#f7a13f\">Vai al video<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du [&hellip;]<\/p>","protected":false},"author":1,"featured_media":33493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,201],"tags":[],"class_list":["post-33487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite","category-recherche-fr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2<\/title>\n<meta name=\"description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/it\/risultati-preliminari-delleroe\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/it\/risultati-preliminari-delleroe\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T06:37:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"articleSection\":[\"Actualit\u00e9\",\"Recherche\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"url\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"description\":\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recherche\",\"item\":\"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/it\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Risultati preliminari promettenti dallo studio HERO per la sindrome - DupMECP2","description":"All'inizio di quest'anno, Alvin Luk ha partecipato alla conferenza CRISPR Medicine di Copenaghen per presentare un aggiornamento sullo studio clinico HERO per la sindrome da duplicazione del gene MECP2. La sua presentazione \u00e8 disponibile su YouTube per la comunit\u00e0.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/it\/risultati-preliminari-delleroe\/","og_locale":"it_IT","og_type":"article","og_title":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2","og_description":"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.","og_url":"https:\/\/dupmecp2.eu\/it\/risultati-preliminari-delleroe\/","og_site_name":"DupMECP2","article_published_time":"2025-05-20T12:00:00+00:00","article_modified_time":"2025-09-10T06:37:22+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Caroline","Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","articleSection":["Actualit\u00e9","Recherche"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","url":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","name":"Risultati preliminari promettenti dallo studio HERO per la sindrome - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","description":"All'inizio di quest'anno, Alvin Luk ha partecipato alla conferenza CRISPR Medicine di Copenaghen per presentare un aggiornamento sullo studio clinico HERO per la sindrome da duplicazione del gene MECP2. La sua presentazione \u00e8 disponibile su YouTube per la comunit\u00e0.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Recherche","item":"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr"},{"@type":"ListItem","position":3,"name":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/it\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/posts\/33487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/comments?post=33487"}],"version-history":[{"count":2,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/posts\/33487\/revisions"}],"predecessor-version":[{"id":33494,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/posts\/33487\/revisions\/33494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/media\/33493"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/media?parent=33487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/categories?post=33487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/it\/wp-json\/wp\/v2\/tags?post=33487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}